Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.020
0.00 (0.00%)
At close: May 22, 2026, 4:00 PM EDT
1.000
-0.020 (-1.96%)
After-hours: May 22, 2026, 6:28 PM EDT

Akebia Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-20.51-5.35-69.41-51.93-94.23-282.02
Depreciation & Amortization
1.281.2737.537.6337.737.97
Stock-Based Compensation
12.7611.287.789.3217.8522.74
Other Adjustments
32.2944.3123.152.32-33.0373.97
Change in Receivables
-1.97-14.144.050.9911.3-24.03
Changes in Inventories
-20.71-23.13-28.4-2.5419.09-24.95
Changes in Accounts Payable
-2.483.08-1.36-5.241.5-11.74
Changes in Accrued Expenses
47.7948.53-12.78-10.02-38.01-22.08
Changes in Unearned Revenue
3.262.68--3.744.651.82
Changes in Other Operating Activities
-4.23-0.55-1.18-0.180.02-24.64
Operating Cash Flow
60.3767.99-40.66-23.38-73.15-252.97
Capital Expenditures
-0.34-0.29-0.03--0.11-0.06
Sale of Property, Plant & Equipment
-0.17----
Purchases of Intangible Assets
--7.81----
Proceeds from Sale of Investments
-----40
Investing Cash Flow
-8.14-7.93-0.03--0.1139.94
Long-Term Debt Issued
-1045---
Long-Term Debt Repaid
-0.49-1.61-37.1-32-33-
Net Long-Term Debt Issued (Repaid)
-0.498.397.9-32-33-
Issuance of Common Stock
3.0568.3643.036.797.688.95
Net Common Stock Issued (Repurchased)
3.0568.3643.036.797.688.95
Other Financing Activities
-0.59-3.83-1.27-4044.78
Financing Cash Flow
-2.9472.9349.66-25.2114.6133.73
Net Cash Flow
49.29132.998.97-48.59-58.67-79.29
Free Cash Flow
60.0467.7-40.69-23.38-73.27-253.02
Free Cash Flow Growth
-11.32%-----
FCF Margin
25.83%28.66%-25.40%-12.02%-25.05%-119.55%
Free Cash Flow Per Share
0.220.26-0.19-0.12-0.40-1.52
Levered Free Cash Flow
15.8234.64-67.76-68.02-102.38-325.7
Unlevered Free Cash Flow
30.3665.35-56.72-30.35-55.94-308.18
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q